Paul Alan Glossop

USPTO Granted Patents = 22 (Patent Applications = 8)

CIPO Patents = 4 (Patent Applications = 9)

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 36(Granted Patents)

Location History:

Kent, GB (2005 - 2006)
Sandwich, Kent, GB (2009)
Sandwich, GB (2006 - 2022)

Company Filing History:

The University of Sheffield

patents

4. 1 out of 832,680

Other

patents

Years Active: 2005-2022

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11400081 - Compounds (2022-08-02),

2. 10065964 - Pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors (2018-09-04),

3. 9533989 - Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors (2017-01-03),

4. 8822439 - Glucocorticoid receptor agonists (2014-09-02),

5. 8486992 - Carboxamide derivatives as muscarinic receptor antagonists (2013-07-16),

6. 8268881 - Carboxamide derivatives as muscarinic receptor antagonists (2012-09-18),

7. 8263583 - Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide (2012-09-11),

8. 8013019 - Sulfonamide derivatives for the treatment of diseases (2011-09-06),

9. 7772223 - Carboxamide derivatives as muscarinic receptor antagonists (2010-08-10),

10. 7767715 - Sulfonamide derivatives for the treatment of diseases (2010-08-03),

11. 7629358 - Compounds useful for the treatment of diseases (2009-12-08),

12. 7547731 - Formamide derivatives for the treatment of diseases (2009-06-16),

13. 7538141 - Compounds for the treatment of diseases (2009-05-26),

14. 7528170 - Sulfonamide derivatives for the treatment of diseases (2009-05-05),

15. 7482487 - Phenylaminoethanol derivatives as β2 receptor agonists (2009-01-27),

Title: The Innovative Journey of Paul Alan Glossop

Introduction

Paul Alan Glossop is a distinguished inventor based in Sandwich, GB, with an impressive portfolio of 21 patents. His inventions primarily focus on pharmacological compounds aimed at treating various diseases, reflecting his commitment to advancing medical science.

Latest Patents

Among his latest patents is a series of compounds that serve as inhibitors of the adrenomedullin receptor subtype 2 (AM). These compounds are not only groundbreaking in their formulation but also promise significant therapeutic benefits for treating proliferative diseases, including cancer. Additionally, he has developed pyrimidine-5-carboxamides that act as spleen tyrosine kinase inhibitors, offering potential treatments for a range of conditions, such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and more. These advanced pharmaceutical compositions also encompass methods for their preparation and the necessary intermediates.

Career Highlights

Throughout his illustrious career, Paul has worked with eminent organizations, notably Pfizer Corporation and Ziarco Pharma Ltd. His experience in these prestigious companies has contributed significantly to his research and innovative capabilities.

Collaborations

Paul has collaborated with various talented individuals, including coworkers Charlotte Alice Louise Lane and Alan Daniel Brown, who have played essential roles in his research endeavors. These partnerships have undoubtedly enriched his inventions, fostering a collaborative spirit within his projects.

Conclusion

Paul Alan Glossop’s contributions to the field of pharmaceuticals through his inventive spirit and collaborative approach demonstrate the profound impact of innovation on healthcare. His patents represent a blend of creativity and scientific rigor, paving the way for new treatments that could benefit countless individuals affected by debilitating diseases.

This text is generated by artificial intelligence and may not be accurate.